Briviact: payments to doctors
Payments that named Briviact as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $7.1M
- Providers
- 16,438
- Transactions
- 143,825
- Average per transaction
- $49
The per-transaction average — $49 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 16,438 providers the average total is $432, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| UCB, Inc. | $6,876,940 | 96.9% |
| UCB SA | $192,506 | 2.7% |
| UCB Biosciences Inc. | $26,114 | 0.4% |
| UCB GmbH | $410 | 0.0% |